New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 21, 2014
09:13 EDTKOOLThermogenesis, TotipotentRX report significant Phase Ib trial results
ThermoGenesis and TotipotentRX announce their co-sponsored Phase Ib clinical trial safety and efficacy results treating no-option patients suffering from critical limb ischemia with Totipotent's Critical Limb Ischemia Rapid Stem cell Therapy, or CLIRST, treatment. The trial achieved both its primary safety and secondary efficacy endpoints at 12 months, achieving statistical significance in five key areas including, major amputation free survival rates, both resting and walking pain reduction, improved walking distance, open wound healing and vasculogenesis in the treated leg. Furthermore, there were no serious adverse events determined to be related to the therapy.
News For KOOL From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
June 25, 2015
06:02 EDTKOOLCesca Therapeutics compliant with Nasdaq listing requirements
Cesca Therapeutics received a letter from Nasdaq Listings Qualifications indicating that the company complies with Nasdaq listing rules because the company has filed its Forms 10-Q for the periods ended December 31, 2014 and March 31, 2015 with the SEC.
June 23, 2015
16:07 EDTKOOLCesca Therapeutics reports Q3 EPS (12c), consensus (10c)
Subscribe for More Information
06:04 EDTKOOLCesca Therapeutics issued patent for stem cells
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use